Novonesis NSIS-B.CO
Novonesis (Novozymes) is a Danish industrial biotechnology company that develops and produces enzymes and microorganisms for a wide range of industries, including detergents, food, feed, and biofuels. Novonesis shows solid financial health (ND/EBITDA of 1.71) and 26.7% earnings growth, but its valuation is demanding (P/E 42.22) and its return on equity is low (ROE 5.77), which moderates the overall appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Novonesis (Novozymes) is a Danish industrial biotechnology company that develops and produces enzymes and microorganisms for a wide range of industries, including detergents, food, feed, and biofuels. Novonesis shows solid financial health (ND/EBITDA of 1.71) and 26.7% earnings growth, but its valuation is demanding (P/E 42.22) and its return on equity is low (ROE 5.77), which moderates the overall appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.5 |
| Quality / Moat | 5.0 |
| Valuation | 3.5 |
| Growth | 7.3 |
| Dividend | 5.7 |
| Momentum | 5.9 |
| Risk & Context | 7.8 |
OVERALL SCORE: 5.8/10
Context and risks
Moderate governance risk in Denmark, although it is a consolidated democracy with strong minority protection. Exposure to emerging markets like India for its expansion adds a minor operational risk, but not material.
News considered in the analysis
- Novozymes (CPSE:NSIS B) Could Be 13% Undervalued After €600 Million Patalganga Expansion — La expansión de capacidad en India es un paso estratégico positivo para el crecimiento a largo plazo, aunque el impacto en beneficios es gradual y ya ha sido parcialmente anticipado por el mercado.
- Novonesis (Novozymes) B's Dividend Analysis — Análisis genérico del dividendo sin información nueva sobre la capacidad de pago o cambios en la política de dividendos.
- FUL or NVZMY: Which Is the Better Value Stock Right Now? — Comparativa genérica de valor entre dos acciones sin información específica y accionable para Novonesis.
- FUL vs. NVZMY: Which Stock Is the Better Value Option? — Listículo de comparación sin datos nuevos sobre la empresa.
- A Look At Novozymes (CPSE:NSIS B) Valuation After Recent Share Price Weakness — Análisis de valoración tras la debilidad del precio, sin información fundamental nueva.
Verdict: Hold; business quality and growth justify the premium, but valuation limits short-term upside potential.
Main risk: The main risk is the demanding valuation (P/E 42.22) which, combined with a low ROE (5.77), leaves little room for error if growth decelerates or interest rates continue to rise in Europe.
Other Basic Materials companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →